Loading…
Scinai Immunotherapeutics Ltd. is projected to decline to $0.3778 by 2027, a -16% move from its current price of $0.4479. SCNI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.4203 | $0.4473 | $0.4761 | -0.12% |
| May 30 | $0.4091 | $0.4468 | $0.488 | -0.25% |
| May 31 | $0.4006 | $0.4462 | $0.4971 | -0.37% |
| Jun 1 | $0.3935 | $0.4457 | $0.5048 | -0.50% |
| Jun 2 | $0.3872 | $0.4451 | $0.5117 | -0.62% |
| Jun 3 | $0.3816 | $0.4446 | $0.5179 | -0.74% |
| Jun 4 | $0.3765 | $0.444 | $0.5236 | -0.86% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3765 | $0.444 | $0.5236 | -0.86% |
| Week 2 | $0.3486 | $0.4402 | $0.5558 | -1.72% |
| Week 3 | $0.328 | $0.4364 | $0.5806 | -2.57% |
| Week 4 | $0.3111 | $0.4326 | $0.6016 | -3.42% |
| Week 5 | $0.2966 | $0.4289 | $0.6201 | -4.25% |
| Week 6 | $0.2839 | $0.4252 | $0.6367 | -5.08% |
| Week 7 | $0.2725 | $0.4215 | $0.652 | -5.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It conducts research and development of IL-17 NanoAb, a VHH-based antibody platform for immune-mediated and inflammatory diseases, including psoriasis, and PC111 for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
The company also provides contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials for biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates, and Recipharm Israel Ltd for the development of biologics and small-molecule programs.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
SCNI is a healthcare stock with a current price of $0.4612 and a market capitalization of $1.83M. It is ranked 5491. The stock trades against visible resistance near $0.74 and below the SMA50 of $0.5995 and the SMA200 of $1.01, suggesting a weaker near-term trend.
The 30-day price range runs from $0.3033 to $0.7013, with near-term support at $0.456 and resistance at $0.74. Forecasts show a mixed price outlook, with 2026 averaging $0.4612 (neutral) and notable long-run upside in some years, including a 2030 average of $0.5659 with ROI 22.7 and a 2050 average of $1.15 with ROI 149.1.
A major floor 43.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 65.2% above — a clean break opens room to run.
A major ceiling 143.4% above — clearing it would confirm fresh momentum.
Key SCNI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SCNI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4734 | Sell | $0.4756 | Sell |
| MA 10 | $0.5012 | Sell | $0.4986 | Sell |
| MA 20 | $0.5586 | Sell | $0.5315 | Sell |
| MA 50 | $0.5899 | Sell | $0.6013 | Sell |
| MA 100 | $0.7144 | Sell | $0.7342 | Sell |
| MA 200 | $0.9956 | Sell | $1.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.21 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -111.18 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -21.13 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.73 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 33.34 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.45 | Sell |
| ADX (14) | 16.30 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is bearish. The RSI(14) is 40, and the price remains below the SMA50 of $0.5995 and the SMA200 of $1.01, signaling a softer near-term trend.
Key levels include support at $0.456 and resistance at $0.74. The 30-day trading range stretches from a low of $0.3033 to a high of $0.7013, illuminating a narrow movement band in the near term. Annualized volatility stands at 100%, underscoring substantial price swings during the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.4479 | $0.4479 | $0.5188 | 0% | Neutral | |
| $0.2718 | $0.3778 | $0.568 | -16% | Bearish | |
| $0.242 | $0.3568 | $0.5704 | -20% | Bearish | |
| $0.2736 | $0.4246 | $0.7117 | -5% | Neutral | |
| $0.3403 | $0.5536 | $0.965 | +24% | Bullish | |
| $0.3004 | $0.5106 | $0.9209 | +14% | Neutral | |
| $0.2664 | $0.4722 | $0.8777 | +5% | Neutral | |
| $0.2435 | $0.4493 | $0.8582 | 0% | Neutral | |
| $0.1967 | $0.3776 | $0.7392 | -16% | Bearish | |
| $0.3012 | $0.6009 | $1.20 | +34% | Bullish | |
| $0.2374 | $0.5275 | $1.16 | +18% | Neutral | |
| $0.4957 | $1.10 | $2.53 | +146% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.4479 | $0.4479 | $0.5344 | +0.00% |
| June 2026 | $0.3676 | $0.4409 | $0.5478 | -1.57% |
| July 2026 | $0.3279 | $0.40 | $0.5098 | -9.28% |
| August 2026 | $0.3165 | $0.3911 | $0.5082 | -2.21% |
| September 2026 | $0.3171 | $0.3963 | $0.523 | +1.32% |
| October 2026 | $0.2913 | $0.3678 | $0.4921 | -7.20% |
| November 2026 | $0.2745 | $0.3497 | $0.4737 | -4.91% |
| December 2026 | $0.2946 | $0.3787 | $0.5188 | +8.29% |
Click any year to see its month-by-month SCNI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SCNI price prediction for 2026 points to an average of $0.4479 (low $0.4479, high $0.5188) — a potential gain of 0% on today's $0.4479. Price action looks broadly range-bound.
In 2027, SCNI is projected to trade between $0.2718 and $0.568, averaging $0.3778 — a potential decline of -16% from today's $0.4479. That is -16% versus the projected 2026 average. Expect choppier, lower action through this leg of the cycle.
Scinai Immunotherapeutics Ltd.'s 2028 outlook centres on $0.3568, within a $0.242 to $0.5704 range. That is -6% versus the projected 2027 average. That marks a -20% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2029, SCNI could reach as high as $0.7117, with a base case around $0.4246 and support toward $0.2736 — roughly -5% from $0.4479. A consolidation phase looks the most probable path here.
Expect SCNI to range from $0.3403 to $0.965 through 2030. The $0.5536 average target implies a +24% move from current prices. That is up +30% on the projected 2029 average. Momentum favours further upside here.
The SCNI price prediction for 2031 points to an average of $0.5106 (low $0.3004, high $0.9209) — a potential gain of +14% on today's $0.4479. A consolidation phase looks the most probable path here.
In 2032, SCNI is projected to trade between $0.2664 and $0.8777, averaging $0.4722 — a potential gain of +5% from today's $0.4479. That is -8% versus the projected 2031 average. Price action looks broadly range-bound.
Scinai Immunotherapeutics Ltd.'s 2033 outlook centres on $0.4493, within a $0.2435 to $0.8582 range. That is -5% versus the projected 2032 average. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, SCNI could reach as high as $0.7392, with a base case around $0.3776 and support toward $0.1967 — roughly -16% from $0.4479. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect SCNI to range from $0.3012 to $1.20 through 2035. The $0.6009 average target implies a +34% move from current prices. That is up +59% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SCNI price prediction for 2040 points to an average of $0.5275 (low $0.2374, high $1.16) — a potential gain of +18% on today's $0.4479. Price action looks broadly range-bound.
In 2050, SCNI is projected to trade between $0.4957 and $2.53, averaging $1.10 — a potential gain of +146% from today's $0.4479. That is up +109% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SCNI today (≈ 2,232.641215 SCNI) could be worth
$2,459.52
+$1,459.52 (+146%) by 2050 · US Dollar
Based on the average projected SCNI price of $1.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SCNIwould be worth at today's price.
$1,000 invested in SCNI on May 27, 2025 (≈ 345.661956 SCNI) would be worth
$154.82
-$845.18 (-84.5%) today · 0.15× · US Dollar
Based on a SCNI entry price of $2.89 vs. today's $0.4479.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.478 | $937.03 | -6.3% |
| 1 month ago | $0.6 | $746.5 | -25.4% |
| 3 months ago | $0.87 | $514.83 | -48.5% |
| 6 months ago | $1.03 | $434.85 | -56.5% |
| 1 year ago | $2.89 | $154.82 | -84.5% |
| All time (5.0y) ago | $309 | $1.45 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SCNI forecast.
Our base-case forecast reaches $0.90 around 2050.
Implied market cap at $0.90: $3.56M
The multi-year forecast shows a pattern of volatility with alternating periods of upside and downside. The 2026 average price is $0.4612 with a neutral sentiment, followed by declines in 2027 ($0.3837 average) and 2028 ($0.368 average), and a rebound in 2029 to $0.4425 average. By 2030, the average rises to $0.5659 with a bullish signal and a 22.7 ROI, with a min of $0.3477 and a max of $0.987.
In the early 2030s, the average price fluctuates: 2031 $0.5281, 2032 $0.4872, 2033 $0.4555, and 2034 $0.3937, with respective ROI values of 14.5, 5.7, -1.2, and -14.6. The 2035 forecast shows a notable uptick to $0.6257 average and 35.7 ROI, with a max of $1.25.
The trajectory continues into 2040 with an average of $0.5427 and 17.7 ROI, and culminates in 2050 with an average of $1.15 and 149.1 ROI, with a max price projected at $2.64. These figures point to potential upside by 2030 and especially by 2050, yet they also reflect substantial volatility and risk across the horizon.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.5659 with a ROI of 22.7 and a min of $0.3477 and a max of $0.987, with a bullish sentiment.
Forecasts show mixed results: some years are bearish (e.g., 2027 ROI -16.8% and 2028 ROI -20.2%), while 2030 shows a positive ROI of 22.7% and 2050 shows 149.1%. The current price is $0.4612 with a market cap of $1.83M, but forecasts are estimates and do not guarantee results.
Yes. The 2035 forecast lists a max of $1.25 and the 2050 forecast lists a max of $2.64, indicating potential to exceed $1 in some scenarios, subject to uncertainty.
Bearish sentiment with RSI(14) at 40. The price is below SMA50 ($0.5995) and SMA200 ($1.01). Support is at $0.456 and resistance at $0.74. The 30-day range is $0.3033 to $0.7013, and annualized volatility is 100%.
Long-term figures show 2030 average $0.5659 with 22.7 ROI, 2040 average $0.5427 with 17.7 ROI, and 2050 average $1.15 with 149.1 ROI, with 2035 at $0.6257 average and 35.7 ROI and a 2050 max of $2.64.
Scinai Immunotherapeutics Ltd. Community Discussion
0Share your Scinai Immunotherapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.